Health-related quality of life in advanced non-small cell lung cancer : a methodological appraisal based on a systematic literature review by van der Weijst, Lotte et al.
SYSTEMATIC REVIEW
published: 12 August 2019
doi: 10.3389/fonc.2019.00715
Frontiers in Oncology | www.frontiersin.org 1 August 2019 | Volume 9 | Article 715
Edited by:
Sacha I. Rothschild,
University of Basel, Switzerland
Reviewed by:
Francesca Mazzoni,
Careggi University Hospital, Italy
Iacopo Petrini,
University of Pisa, Italy
*Correspondence:
Lotte Van Der Weijst
lotte.vanderweijst@ugent.be
Specialty section:
This article was submitted to
Thoracic Oncology,
a section of the journal
Frontiers in Oncology
Received: 19 April 2019
Accepted: 18 July 2019
Published: 12 August 2019
Citation:
Van Der Weijst L, Lievens Y,
Schrauwen W and Surmont V (2019)
Health-Related Quality of Life in
Advanced Non-small Cell Lung
Cancer: A Methodological Appraisal
Based on a Systematic Literature
Review. Front. Oncol. 9:715.
doi: 10.3389/fonc.2019.00715
Health-Related Quality of Life in
Advanced Non-small Cell Lung
Cancer: A Methodological Appraisal
Based on a Systematic Literature
Review
Lotte Van Der Weijst 1*, Yolande Lievens 1, Wim Schrauwen 2 and Veerle Surmont 3
1Department of Radiotherapy-Oncology, Ghent University Hospital, Ghent, Belgium, 2Department of Medical Oncology,
Ghent University Hospital, Ghent, Belgium, 3Department of Thoracic Oncology, Ghent University Hospital, Ghent, Belgium
Background: The majority of lung cancer patients are diagnosed with advanced
non-small cell lung cancer (NSCLC), the bulk of which receive palliative systemic
treatment with the goal to provide effective symptom palliation and safeguard
health-related quality of life (HRQoL). Advanced NSCLC trials with HRQoL endpoints
face methodological constraints limiting interpretability.
Objectives: We provide a comprehensive overview of recent clinical trials evaluating
the impact of systemic therapies on HRQoL in advanced NSCLC, focusing on the
methodological quality, with the ultimate goal to improve interpretation, comparison and
reporting of HRQoL data.
Methods: A systematic literature review was performed. Prospective studies published
over the last decade evaluating the impact of systemic treatments on HRQoL in advanced
NSCLC were included. Methodological quality of HRQoL reporting was assessed with
the CONSORT-PRO extension.
Results: Hundred-twelve manuscripts describing 85 trials met all criteria. No formal
conclusion can be drawn regarding the impact on HRQoL of different treatments. We
report an important variety in methodological quality in terms of definitions of HRQoL,
missing data points, lack of standardization of analyzing and presenting HRQoL and
no standard follow-up time. The quality of HRQoL data reporting varies substantially
between studies but improves over time.
Conclusion: This review shows that in the heterogeneous landscape of trials addressing
HRQoL in advanced stage NSCLC. Methodology reporting remains generally poor.
Adequate reporting of HRQoL outcome data is equally important to support clinical
decision-making as to correctly inform health policy regarding direct approval and
reimbursement of the new drugs and combinations that will come online.
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INTRODUCTION
Lung cancer contributes to 1.6 million deaths a year, making
it the deadliest cancer worldwide (1). Approximately 80% of
primary lung cancers are non-small cell lung cancer (NSCLC)
(2). Locally advanced (stage IIIB) or metastatic (stage IV)
NSCLC is diagnosed in most patients (65%), leading, despite the
development of novel systemic therapies, to poor 5-years survival
rates of 5 and 1%, respectively. Palliative therapy aims to prolong
survival and to offer acceptable quality of life (QoL). The latter
is especially important because besides poor survival, patients
with advanced NSCLC also frequently suffer from high symptom
burden and toxic therapeutic side effects (3).
Health-related quality of life (HRQoL) has become an
integral endpoint in clinical trials for advanced cancer (4,
5). HRQoL is a multi-dimensional concept that addresses the
functional effect of a health status and/or a patient’s treatment.
It embodies physical, role, emotional, social, cognitive, sexual
and spiritual functioning on individual levels (6–8). HRQoL
data enables treatment comparisons, supports daily clinical
treatment decision-making, improves communication between
patients and treating clinicians and facilitates clinical and
economic evaluations to define the most efficient allocation
of healthcare resources (3). Patient-reported HRQoL data
particularly aids clinicians to better understand toxicity and
symptoms experienced by patients, as subjective symptoms,
such as fatigue and pain are frequently under-reported (9).
Finally, baseline HRQoL is an independent predictive value for
therapy response and survival (5, 10–13), performing better
than certain classic endpoints, such as performance status
(5). In order to guide treatment decision making and health
policy, qualitative reporting and analysis of HRQoL outcomes
are essential. Methodological flaws might lead to inaccurate
interpretation of outcomes and hinder implementation in clinical
practice. Correspondingly, poor data quality and methodological
concerns have limited the influence of HRQoL data on the Food
and Drug Administrations’ regulatory decision making process
(3). Methodological constraints in HRQoL data reporting and
analysis have been previously highlighted (5).
A number of systematic literature reviews have already
been conducted on clinical trials using HRQoL endpoints in
patients with advanced NSCLC, all studying a specific question
(Table 1). This systematic literature review aims to add to the
available evidence by providing a comprehensive overview of all
prospective studies published over the last decade, evaluating
the impact of various systemic treatments on HRQoL in
advanced NSCLC. In addition, the methodological quality of
this set of papers is analyzed with the ultimate goal to discuss
challenges in and recommendations for the interpretation and
comparison of HRQoL evidence obtained from randomized-
controlled trials (RCTs).
MATERIALS AND METHODS
Literature Search
A literature search, following the PRISMA principles (23), was
performed in Medline, Web of Science and Embase with both
systematic and free text terms concerning HRQoL, advanced and
NSCLC (Figure 1). The last search was performed May 29, 2018.
Study Selection
The search focuses on articles published between January
2007 and December 2017, including those electronically
available within this period. Non-randomized trials, pilot and
retrospective studies, abstracts without manuscript and non-
English articles were excluded. Articles were eligible if the study
population included patients with stage IIIB and/or IV NSCLC
receiving palliative systemic therapy and measuring HRQoL for
more than one time points. Secondary articles, covering the
same study population as the primary article, were included
and combined into the data synthesis, provided they added
information concerning HRQoL.
Data Extraction
Study selection was two-staged. Firstly, title and abstract
screening against selection criteria was undertaken by a
single reviewer (LVDW). The other authors were consulted
for disagreement resolution. Secondly, full-text articles were
extracted based on the eligibility criteria to select the final sample
of studies.
Methodological Quality
The quality of HRQoL data reporting of the included studies was
assessed with the CON-solidated Standards of Reporting Trials
(CONSORT)—Patient-ReportedOutcomes (PRO) checklist (24).
The five PRO-specific minimum recommendations for reporting
randomized controlled trials were used to assess quality
of reporting.
Cut-off scores for reporting quality are: “good” ≥80%;
“moderate” 50–79%; and “poor” ≤49% (24). In case items
were not applicable, such as allocation concealment mechanism,
they were excluded in the total outcome. In case secondary
manuscripts were published on HRQoL outcomes, both the
primary and secondary manuscript were included in the
quality assessment.
RESULTS
Eleven hundred and twenty-two abstracts were identified for
initial review. A total of 308 articles underwent in-depth analysis.
Of these, 112 articles representing 85 trials were included in this
review. The review process is summarized in Figure 1.
Study Characteristics
In brief, 34,897 patients were enrolled in 85 RCTs, ranging
from 37 to 1,433 patients per study. Most of the identified
literature presented phase III (n = 59; 69%) RCTs. Fifty-nine
studies (69%) analyzed first-line therapy. The most frequently
used primary (co-) endpoint was survival (n= 34; 40%), followed
by progression free survival (PFS) (n = 32; 38%), response rate
(n= 9; 11%) and QoL (n= 6; 7%).
In total, 41 studies compared different chemotherapies,
4 studies compared different targeted therapies. Twenty
studies compared chemotherapy with targeted therapy; 1 with
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TABLE 1 | Overview of systematic literature reviews of HRQoL in advanced NSCLC trials published since 2007 in chronological order.
References Title Purpose Time frame Conclusions Limitations
Tanvetyanon et al.
(14)
A systematic review of quality of life
associated with standard
chemotherapy regimens for advanced
non-small cell lung cancer.
To evaluate the effect
of standard
chemotherapy
regimens.
January
1966–May 2006
No large varieties between
chemotherapies have been
found. HRQoL outcome
comparisons are hardly
feasible due to
heterogeneity and low
compliance to HRQoL
evaluations.
Focuses solely on
chemotherapy. Only
13 articles are
included.
Pat et al. (15) Systematic review of symptom
control and quality of life in studies on
chemotherapy for advanced
non-small cell lung cancer: how
CONSORTed are the data?
To evaluate
compliance to the
CONSORT checklist
in RCT comparing
chemotherapy.
1980–August
2005
Compliance to CONSORT is
reasonable. Large
differences between
journals and no
improvements were found.
Focuses solely on
chemotherapy.
Claassens et al. (16) Health-related quality of life in
non-small-cell lung cancer: an update
of a systematic review on
methodologic issues in randomized
controlled trials.
To evaluate HRQoL
measurements
2002–2010 Incorporation of HRQoL
endpoints has increased.
Quality of HRQoL
methodology reporting has
improved, however specific
domains remain
inadequately reported.
Focuses on the
qualitative aspects
of HRQoL reporting.
Matsuda et al. (17) Quality of life in advanced non-small
cell lung cancer patients receiving
palliative chemotherapy: a
meta-analysis of randomized
controlled trials.
To provide an
overview of HRQoL in
chemotherapy trials.
Until April 2010 Carboplatin-based
chemotherapy is associated
with better global QoL than
cisplatin-based
chemotherapy.
Focuses on the
comparison of
carboplatin- to
cisplatin-based
chemotherapy. Only
6 trials are included.
Ganguli et al. (18) The impact of second-line agents on
patients’ health-related quality of life
in the treatment for non-small cell
lung cancer: a systematic review.
To assess HRQoL in
second-line
treatment trials.
2000–2010 Improvement in overall QoL
were inconsistent. Large
varieties in methodology
hinders comparisons.
Focuses solely on
second-line
chemotherapy.
Saad et al. (19) Assessment of quality of life in
advanced non-small-cell lung cancer:
an overview of recent randomized
trials.
To provide an
overview of trials with
HRQoL endpoints.
1997–2009 The majority of trials
incorporate HRQoL
endpoint. Almost half of
included trials reported a
significant difference.
Articles published
only in 13 leading
journals.
Damm et al. (3) Health-related quality of life
questionnaires in lung cancer trials: a
systematic literature review.
To evaluate the
HRQoL
measurements used
in trials.
2001–2011 Wide range of HRQoL
questionnaires was used.
The EORTC QLQ-C30 and
its lung cancer specific
module was the most
frequently used.
Focuses mainly on
HRQoL
questionnaires.
Mannion et al. (20) Effect of chemotherapy on quality of
life in patients with non-small cell lung
cancer.
To evaluate HRQoL in
palliative
chemotherapy trials.
1987–2011 QoL is an important
outcome in advanced
NSCLC.
Focuses solely on
chemotherapy.
Fiteni et al. (21) Methodology of health-related quality
of life analysis in phase III advanced
non-small-cell lung cancer clinical
trials: a critical review.
To evaluate the
methodology of
HRQoL analysis and
reporting in phase III
first-line
chemotherapy trials.
2008–2014 Shortcomings and
heterogeneity in
measurement, analysis and
reporting of HRQoL.
Comparisons of HRQoL
between trials remains
therefore difficult.
Focuses on the
methodology of
HRQoL analysis in
phase III trials of
first-line
chemotherapy.
Bouazza et al. (22) Patient-reported outcome measures
(PROMs) in the management of lung
cancer: a systematic review.
To describe and
compare available
PROMs.
January
2010–February
2016
PROMs are important in
clinical practice if introduced
adequately.
Focuses on PROMs
rather than HRQoL.
immunotherapy. Respectively, 14 and 1 studies compared
targeted and chemotherapy to placebo. Four studies compared
different sequential therapies consisting of both targeted
therapy and chemotherapy. A brief synopsis of the main study
characteristics is presented in the Supplementary Material.
Figure 2A provides an overview of studies incorporating
different therapies per year, illustrating that the interest for the
HRQoL impact of systemic treatments progressively shifted from
chemotherapy to chemotherapy vs. targeted therapy and targeted
therapy vs. placebo.
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FIGURE 1 | Flow chart describing the selection of eligible manuscripts.
Impact of Systemic Treatments on HRQoL
Twenty-six (31%) studies found a statistically or minimal
clinically important difference (MCID) in HRQoL between
therapy arms. Furthermore, some reported a difference in certain
domains or symptoms. MCID refers to smallest change in an
outcome that is important to the patient (25). Respectively, 22%
(n= 9) (26–36) and 50% (n= 2) (37–39) of the trials assessing the
impact on HRQoL of various chemotherapeutic combinations
and different targeted therapies reported a difference. The only
trial (40, 41) comparing chemotherapy to placebo reported
no difference, only 2 out of 14 studies showed that targeted
therapy causes a positive impact on HRQoL compared to placebo
(42–44). Eleven studies (55%) comparing chemo- with targeted
therapy reported a difference (45–60), with targeted therapy
favored in nine. One study reported that gefitinib is favored
in patients with EGFR mutations and carboplatin/paclitaxel in
those without mutations (61, 62). The only study comparing
chemotherapy to immunotherapy favored the latter (63, 64). One
out of 4 sequential therapy RCTs reported a difference between
arms (65, 66). The results are summarized in Figure 2B.
Quality of HRQoL Data
Eighteen different HRQoL measurement tools were used,
including generic, cancer-, lung cancer-, and symptom specific
tools. The cancer-specific European Organization for Research
and Treatment of Cancer Quality of Life Questionnaire (EORTC
QLQ-C30) alone or together with its lung cancer-specific EORTC
QLQ-LC13 supplementary module was the dominantly used
HRQoL instrument (n = 38; 45%). The Functional Assessment
of Cancer Therapy-Lung (FACT-L) questionnaire was employed
27 (32%) times and the lung cancer symptom scale (LCSS) tool
was used in 11 (13%) trials.
HRQoL data analysis is based on a large variety of statistical
techniques, ranging from Mann–Whitney U test (n = 11;
13%), logistic regression model (n = 8; 9%) to t-test (n = 6;
7%). Twenty-three studies lacked clarification on statistical
methods applied.
The quality of HRQoL reporting is summarized in Table 2.
Figure 3 provides a comprehensive overview of the quality
aspects concerning PROs of each individual study. All PRO items
were scored poorly, except for identification PRO as a primary or
secondary outcome in the abstract which was scored moderate.
Only one study fulfilled all criteria (67, 68).
DISCUSSION
A number of systematic literature reviews on HRQoL in
advanced NSCLC trials have already been conducted (Table 1),
all focusing on specific treatments or aspects. This review
addresses the entire spectrum of nowadays’ systemic treatment
strategies, newer drugs as well as chemotherapy, in trials
published over the last 10 years. In addition, in contrast to the
other reviews, it provides both a synopsis of study characteristics
and methodological quality of HRQoL reporting.
Maintenance and improvement of HRQoL in advanced
NSCLC as a result of treatment is important due to the limited
impact which therapies have on prolonging life. A qualitative
study on chemotherapy preferences reported that advanced
NSCLC patients favor chemotherapy over best supportive care
in case HRQoL improves with chemotherapy, even without
improving survival (69). Accordingly, the Food and Drug
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FIGURE 2 | (A) Overview of different therapies incorporated in clinical trials over the last 10 years. *Based on the year of HRQoL publication; CT, chemotherapy vs.
chemotherapy or placebo; TT, targeted therapy vs. targeted therapy or placebo; CT vs. TT, chemotherapy vs. targeted therapy; sequential: sequential therapy
consisting of both targeted and chemotherapy; CT vs. IM, chemotherapy vs. immunotherapy. (B) Overview of clinical trials with/without significant differences in
HRQoL between therapy arms over the last 10 years. *Based on the year of HRQoL publication; MCID, meaningful clinically important difference.
Administration started approving new drugs, such as erlotinib,
based on the combination of longer PFS with positive impact
on HRQoL or other PROs, without significantly improving
overall survival. To-date however, the patient perspective is
not yet fully embedded in drug approval, and when PROs are
used, they are typically limited to improvement in symptoms
rather than HRQoL (70). It has however been shown that
PROs are more strongly associated with measures of daily
health status than clinician assessment (71). High quality
patient-reported HRQoL data may therefore provide meaningful
information for risk-benefit evaluation and should be used
to support drug approval and reimbursement policy. In this
review, 85 studies on advanced NSCLC with HRQoL end-
points were identified, enrolling almost 35,000 patients. Despite
these large numbers, the vast heterogeneity of agents used
does not allow one to draw overall conclusions, nor on the
actual HRQoL gains, nor on the most effective drugs to
improve HRQoL. Based on the study results, targeted therapies
seem to be favored over chemotherapy in terms of HRQoL,
but interpretation on a case by case basis remains necessary.
One review concluded that carboplatin-based chemotherapy
is associated with better global QoL compared to cisplatin-
based regimes; no other conclusions were drawn in the
reviews (17).
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TABLE 2 | Summary of quality of HRQoL reporting.
PRO-specific extensions % (n)
P1b: The PRO should be identified in the abstract as a
primary or secondary outcome
60% (51/85)
P2b: The PRO hypothesis should be stated and relevant
domains identified, if applicable
13% (11/85)
P6a: Evidence of PRO instrument validity and reliability
should be provided or cited if available including the
person completing the PRO and methods of data
collection
6% (5/85)
P12a: Statistical approaches for dealing with missing
data are explicitly stated
18% (15/85)
P20/21: PRO-specific limitations and implications for
generalizability and clinical practice
31% (26/85)
“Good” ≥80%.
“Moderate” 50–79%.
“Poor” ≤49%.
Although, only one immunotherapy RCT has been included
in this review, immunotherapy is an emerging and continuously
evolving field within thoracic oncology. The first data on HRQoL
from immunotherapy trials is now appearing. These initial results
show that HRQoL ismaintained and improvedmore significantly
with immunotherapy compared to chemotherapy (72–75). More
data onHRQoL in immunotherapy is expected in the near future.
In addition to the actual outcome data supporting clinical
decision-making, consistency in collecting, analyzing and
reporting HRQoL data is important to guide health policy.
Especially in an era where new, expensive and potentially
toxic drug combinations are frequent. HRQoL data may have
an impact on reimbursement policies. Previous studies have
highlighted the multidimensional nature of HRQoL, diversity in
research questions, lack of a priori hypothesis, repeated measures
and high likelihood of missing data which hampers drawing
meaningful conclusions (76). Standardization—in HRQoL end-
points included in trials, in analysis and reporting of HRQoL
data—is, therefore, needed. Paucity of standardization limits
the interpretability and comparability of HRQoL data between
therapies and has implications on decision-making (3). The
Setting International Standards in Analyzing Patient-Reported
Outcomes and Quality of Life Endpoints Data (SISAQOL)
consortium has been established to develop recommendations
on analysis and interpretation of PROs in oncology trials (76).
When designing an oncology trial with HRQoL endpoints and
interpreting HRQoL data, in the future it will be important to
consult the recommendations of the SISAQOL. Furthermore,
HRQoL results should be presented according to the CONSORT-
PRO checklist, aiming to facilitate optimal reporting of PRO
data in RCTs (24). Several HRQoL data capturing tools
are used, including generic, condition- and symptom-specific
questionnaires. Outcome data derived from these questionnaires
differ substantially in terms of HRQoL parameters and lung
cancer-associated symptoms (3). Montazeri et al. recommends
using the EORTC QLQ-C30 questionnaire and its lung cancer-
specific module (QLQ-LC13) in lung cancer trials (77, 78).
However, since the introduction of the QLQ-LC13 in 1994, major
developments have occurred in the diagnosis and treatment
of lung cancer. The EORTC has recognized this challenge
and has therefore updated this questionnaire (QLQ-LC29),
encompassing the impact of new and innovative treatment
strategies on HRQoL (79).
The EORTC QLQ C30 is used in almost half of the analyzed
studies. Yet inter-comparison among studies remains difficult
as some selectively report certain domains or symptoms of
HRQoL, for example an improvement in cough, pain, dyspnea
and physical functioning using erlotinib, without mentioning
the remaining HRQoL parameters (80). Other studies solely
report significant differences between treatment arms, but lack
reporting on whether HRQoL is maintained, improved or
whether it deteriorates (81–83). Other studies report percentile
symptom improvements or the mean HRQoL deterioration time
(55), moreover, the majority of RCTs stop HRQoL measurement
some months after end of therapy or solely rely on HRQoL
evaluations during and at the end of treatment, not capturing
long-term effects. Although toxicities associated with targeted
and chemotherapy regimens, influencing HRQoL, may be either
reversible or continue to prevail during most of the patient’s life,
recommendations on duration of the follow-up period are still
inexistent (84).
From a statistical point of view, an even larger variation exists.
If longitudinal HRQoL data is available, standardized approaches
to analyze and define MCID scores are necessary. MCID should
be applied, as statistically significant improvement or worsening
of HRQoL scores may be too small to be clinically relevant
to the patient (85). As mentioned, the lack of standardization
hinders drawing conclusions on the clinical meaningfulness of
HRQoL data, hence, assisting treatment decisions (3). As a result
of these issues, the SISAQOL consortium was established in
2016 (76). Missing multiple data points also remains problematic
and seems inevitable in longitudinal HRQoL datasets in the
advanced NSCLC population (5). Patients with poor health at
baseline typically have poor baseline HRQoL, may have worse
disease progression and have a HRQoL that deteriorates faster.
These patients generally drop out earlier than patients with
better baseline HRQoL. This potentially leads to bias, affects
trial results and conclusions, and eventually clinical practice.
(68, 86). Accordingly, missing data in repeated measurements
over time combined with the multidimensionality of HRQoL
data requires statistical analysis techniques capable of dealing
with these issues (69).
Qualitative and complete reporting of HRQoL results
in scientific articles is crucial to allow applying HRQoL
evidence from clinical trials into daily clinical decision-making
and treatment policies. Our data demonstrates persisting
inadequate presentation of specific domains and overall poor
reporting quality, not dissimilar from the observations made
in previous reviews (16). The limited methodological quality
and lack of certain crucial aspects hinders comparing and
interpreting HRQoL data, necessary to support optimal decision-
making, problematic.
Apart from the quality issues described, the very nature
of clinical trials per se may hamper translating evidence into
practice. Strict inclusion criteria concerning age and performance
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FIGURE 3 | Overview of the quality aspects of PROs of each individual studies.
status limit the overall generalization of HRQoL data. Of the
85 analyzed studies, only 12 focused particularly on elderly
patients, whereas they represent the majority of the lung cancer
patient population (35, 46, 47, 49, 67, 68, 87–93). Hence,
collecting HRQoL real-life data has added value to determine
the best standard of care and to define the most efficient
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healthcare resource allocation involving patients with advanced
NSCLC (20).
Finally, although this review aimed to provide a
comprehensive review of the recent peer-reviewed literature,
it may have failed to capture potentially important evidence,
as only full-text publications were included and studies not
published in English excluded. The exclusion of gray literature
has nonetheless been applied to guarantee the validity of the
included articles in terms of methodological quality (94).
Another factor to be considered is that the publication period
was restricted to 10 years, in order to capture evidence on the
drugs most relevant to date.
CONCLUSION
Our systematic review provides a comprehensive overview of
recent RCTs evaluating the impact of systemic therapies on
HRQoL in advanced NSCLC. It focuses on the methodological
quality of these papers.
A vast variety in HRQoL measurements, data collection time
points and reporting and analyzing of HRQoL data makes
comparisons of outcomes hardly feasible. Quality of reporting
HRQoL outcomes remains poor with certain aspects being
systematically underreported.
Nevertheless, adequate and complete reporting is critical to
inform health policy and clinical decision-making to sustain
and improve HRQoL in this critical patient population.
This is particularly important since new, expensive and
potentially toxic therapies, often in combination, are
being introduced.
Future clinical trials exploring novel therapies for advanced
NSCLC should focus on reporting HRQoL data in a clinically
meaningful and methodologically qualitative way. Additionally,
further research should focus on developing standards to
optimize and on defining MCID scores.
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